肺癌DNA倍体及增殖活性与病理特征的关系  

Relationship between DNA Content,Proliferative Activity and Pathological Feature in Lung Carcinoma

作　　者：沈玉光[1] 李伟光[2] 魏冰[1] 丁志丹[1] 何山宏[1] 程金华[1] 许金良[1] 

机构地区：[1]河南省肿瘤医院,郑州市450008 [2]河南中医学院第三附属医院,郑州市450008

出　　处：《医药论坛杂志》2007年第23期30-31,34,共3页Journal of Medical Forum

摘　　要：目的探讨肺癌组织DNA含量(DI)、合成期细胞比例(SPF)、增殖指数(PI)与临床病理特征间的关系。方法应用流式细胞仪测定73例新鲜肺癌组织细胞的DI、SPF、PI值,研究其和肺癌临床病理的关系。结果异倍体率、DI、SPF、PI等指标在以患者性别、肿瘤病理类型、淋巴结转移、TNM分期等病理特征为分组对象的各组间没有发现显著性差异。结论①肺癌DNA倍体改变发生在癌变早期,其后其细胞DNA的改变随着病程进展没有发生明显改变;②肺癌DAN倍体、增殖活性在患者性别、病理类型、淋巴结转移、TNM分期等各组间没有显著性差异。Objective To investigate the relationship between DNA,cell cycle analysis and the pathological feature in lung carcinoma.Methods Flow cytometry was used to measure DNA ploidy and synthesis-phase fraction（SPF）of the resected lung tissues from 73 patients with lung carcinoma.Results DNA aneuploidy was present in 54（74%）of the 73 patients.There were no significant differences in DNA ploidy,SPF,and the clinicopathological features such as sex,pathological type,TNM stage,lymph node involvement.Conclusion There were no significant corelation between DNA ploidy,SPF,and the patient＇s clinicopathological features such as sex,pathological type,TNM stage or lymph node involvement in this study.

关 键 词：肺癌 流式细胞术 DNA倍体 增殖活性 病理 

分 类 号：R734.2[医药卫生—肿瘤]